Spurring move to personalized therapies, Loxo elbows its way back into the ASCO spotlight with 2nd tissue-agnostic cancer drug success
CHICAGO — With their lead drug — and ASCO17 star — larotrectinib making the final run-up to a widely expected approval in November, Loxo Oncology …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
